scholarly journals T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics

2018 ◽  
Vol 9 (11) ◽  
Author(s):  
Katharine J. Herbert ◽  
Thomas M. Ashton ◽  
Remko Prevo ◽  
Giacomo Pirovano ◽  
Geoff S. Higgins
Keyword(s):  
2010 ◽  
Vol 285 (38) ◽  
pp. 29138-29146 ◽  
Author(s):  
Tatyana A. Zykova ◽  
Feng Zhu ◽  
Tatyana I. Vakorina ◽  
Jishuai Zhang ◽  
Lee Ann Higgins ◽  
...  

2016 ◽  
Vol 22 (24) ◽  
pp. 6110-6117 ◽  
Author(s):  
Yuji Ikeda ◽  
Jae-Hyun Park ◽  
Takashi Miyamoto ◽  
Naofumi Takamatsu ◽  
Taigo Kato ◽  
...  

2019 ◽  
Vol 39 (4) ◽  
Author(s):  
Xin Diao ◽  
Danfen Yang ◽  
Yu Chen ◽  
Wentian Liu

AbstractBaicalin is the main bioactive component extracted from the traditional Chinese medicine Baical Skullcap Root, and its anti-tumor activity has been studied in previous studies. PDZ-binding kinase/T-LAK cell-originated protein kinase (PBK/TOPK), a serine/threonine protein kinase, is highly expressed in many cancer cells and stimulates the tumorigenic properties, and so, it is a pivotal target for agent to cure cancers. We reported for the first time that baicalin suppressed PBK/TOPK activities by directly binding with PBK/TOPK in vitro and in vivo. Ex vivo studies showed that baicalin suppressed PBK/TOPK activity in JB6 Cl41 cells and H441 lung cancer cells. Moreover, knockdown of PBK/TOPK in H441 cells decreased their sensitivity to baicalin. In vivo study indicated that injection of baicalin in H441 tumor-bearing mice effectively suppressed cancer growth. The PBK/TOPK downstream signaling molecules Histone H3 and ERK2 in tumor tissues were also decreased after baicalin treatment. Taken together, baicalin can inhibit proliferation of lung cancer cells as a PBK/TOPK inhibitor both in vitro and in vivo.


2010 ◽  
Vol 101 (2) ◽  
pp. 403-411 ◽  
Author(s):  
Jae-Hyun Park ◽  
Toshihiko Nishidate ◽  
Yusuke Nakamura ◽  
Toyomasa Katagiri
Keyword(s):  

2017 ◽  
Vol 38 (2) ◽  
pp. 144-153 ◽  
Author(s):  
Tomohide Hayashi ◽  
Yumiko Hayakawa ◽  
Masaki Koh ◽  
Takahiro Tomita ◽  
Shoichi Nagai ◽  
...  

2021 ◽  
Vol 2021 ◽  
pp. 1-16
Author(s):  
Tingting Feng ◽  
Yan Zhang ◽  
Sunbin Ling ◽  
Chenyang Xu ◽  
Yingqi Lyu ◽  
...  

Background. PDZ binding kinase (PBK)/T-LAK cell-derived protein kinase (TOPK) is an important mitotic kinase that promotes tumor progression in some cancers. However, the pan-cancer analysis of PBK/TOPK and its role in tumor immunity are limited. Methods. The oncogenic and immune roles of PBK in various cancers were explored using multiple databases, including Oncomine, Human Protein Atlas, ULCAN, Tumor Immune Estimation Resource 2.0, STRING, and Gene Expression Profiling Interactive Analysis 2, and data collected from The Cancer Genome Atlas and Genotype-Tissue Expression Project. Several bioinformatics tools and methods were used for quantitative analyses and panoramic descriptions, such as the DESeq2 and Tumor Immune Dysfunction and Exclusion (TIDE) algorithm. Results. PBK was expressed at higher levels in most solid tumors than in normal tissues in multiple databases. PBK was associated with an advanced tumor stage and grade and a poor prognosis in most cases. PBK was associated with tumor immune cell infiltration in most cases and was especially positively correlated with TAMs, Tregs, MDSCs, and T cell exhaustion in KIRC, LGG, and LIHC. PBK was closely related to TMB, MSI, and immune checkpoint genes in various cancers, and patients with higher expression of PBK in KIRC, LGG, and LIHC had higher TIDE scores and lower immune responses in the predicted results. PBK was closely related to cell cycle regulation and immune-related processes in LIHC and LGG according to GO and KEGG enrichment analyses. Conclusions. PBK may play an oncogenic role in most solid tumors and promotes immune escape, especially in KIRC, LGG, and LIHC. This study suggests the potential value of PBK inhibitors combined with immunotherapy.


2019 ◽  
Vol 10 (1) ◽  
pp. 131-137 ◽  
Author(s):  
Yi Zhang ◽  
Xianjin Yang ◽  
Rong Wang ◽  
Xu Zhang

Sign in / Sign up

Export Citation Format

Share Document